Non-Small Cell Lung Cancer | John V Heymach, MD, PhD

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer— Faculty Presentation 2: Therapeutic Approaches for Patients with Actionable Genomic Alterations Beyond EGFR, ALK and ROS1 — John V Heymach, MD, PhD. CME information and select publications